Vincerx Pharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Vincerx Pharma şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-198.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-198.2%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: VINC şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: VINC şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Vincerx Pharma Piyasaya Karşı Temettü Getirisi

VINC temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (VINC)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (VINC) (3 yıla kadar)	n/a

Önemli Temettü: VINC şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, VINC şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: VINC şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: VINC herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Vincerx Pharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Shareholder dilution

New major risk - Market cap size

Price target decreased by 14% to US$6.00

Vincerx Pharma, Inc. Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline

Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely

New major risk - Financial position

Insufficient new directors

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

Vincerx Pharma, Inc. has completed a Follow-on Equity Offering.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering.

Vincerx Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research (Aacr) Annual Meeting 2024

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Vincerx Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 35% to US$9.00

New major risk - Share price stability

Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

New major risk - Financial position

New major risk - Revenue and earnings growth

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma Receives Non-Compliance Notice from the Nasdaq Stock Market

Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

New major risk - Financial position

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Vincerx Pharma, Inc. Announces Resignation of Board of Directors

Vincerx Pharma Announces Fda Safe to Proceed Letter for Investigational New Drug (Ind) Application for Its <Alpha>V<Beta>3 Small Molecule-Drug Conjugate (Smdc) Vip236

Price target decreased to US$8.40

Vincerx Pharma, Inc. Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Price target decreased to US$12.60

High number of new and inexperienced directors

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Founder recently bought US$56k worth of stock

Vincerx Pharma, Inc.(NasdaqCM:VINC) dropped from Russell 2000 Growth Index

Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022

Vincerx Pharma, Inc. Provides Clinical Updates

Price target decreased to US$21.33

High number of new and inexperienced directors

Vincerx, Inc., Annual General Meeting, May 26, 2022

Price target decreased to US$23.86

Price target decreased to US$26.57

High number of new and inexperienced directors

Founder recently bought US$65k worth of stock

Vincerx Pharma, Inc. Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Independent Director recently bought US$126k worth of stock

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors

Vincerx Pharma doses first patient in early-stage VIP152 cancer study

Independent Director has left the company

Vincerx Pharma, Inc. Announces Management Appointments

Vincerx Pharma, Inc., Annual General Meeting, May 13, 2021

Vincerx, Inc. Announces Executive Changes

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin